The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer

• Main Authors: Gennadi Tulchiner, Nina Staudacher, Josef Fritz, Christian Radmayr, Zoran Culig, Wolfgang Horninger, Renate Pichler
• Format: Article
• Language: English
• Published: MDPI AG 2021-04-01
• Series: Cancers
• Subjects: bladder cancer; urothelial cancer; COVID-19; pandemic; lockdown; diagnosis
• Online Access: https://www.mdpi.com/2072-6694/13/8/1754

Coronavirus-19 (COVID-19)-induced effects on deferred diagnosis and treatment of bladder cancer (BC) patients are currently not clarified. The aim of this study was to evaluate outcomes of the COVID-19 pandemic by considering its effects on tumor stage and grade, and to create feasible clinical triage decisions. A retrospective single-center analysis of all patients who underwent diagnostic and surgical procedures due to BC, during January 2019 and December 2020, was performed. Due to COVID-19 lockdowns, significantly fewer (diagnostic and therapeutic) endoscopic procedures were performed in the first 6 months of 2020 compared to 2019 (<i>p</i> = 0.002). In patients with a primary diagnosis of BC, a significant increase of high-grade tumors (<i>p</i> < 0.001), as well as advanced tumor stages (<i>p</i> = 0.014), were noticed during 2020 in comparison to 2019. On the contrary, patients with recurrent BC undergoing risk-adapted surveillance, depending on previous tumor histology, showed no adverse outcomes regarding tumor stage and grade when comparing the pre COVID-19 era with 2020. Thus, more awareness in clinical urologic practice is mandatory to avoid adverse consequences, with increased rates of advanced and aggressive tumors in patients with primary BC. In recurrent BC, an individual risk stratification in order to avoid worse outcomes during the COVID-19 pandemic seems to be justified.